The Medicines Company's Cangrelor Bridge Trial Published in the Journal of the American Medical Association

(firmenpresse) - PARSIPPANY, NJ -- (Marketwire) -- 01/17/12 -- The Medicines Company (NASDAQ: MDCO) today announced publication in the Journal of the American Medical Association (JAMA) of clinical trial results from testing of cangrelor, an investigational intravenous antiplatelet.

The article, "Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery," is available in the January 18 JAMA issue under Original Contributions.

Cangrelor is an investigational intravenous small molecule antiplatelet agent not approved for commercial use in any market. BRIDGE is a prospective, randomized, double-blind, placebo-controlled multicenter trial which evaluated cangrelor or placebo in 210 patients with an acute coronary syndrome (ACS) or treated with a coronary stent and receiving a thienopryidine awaiting coronary artery bypass graft (CABG) surgery. The primary efficacy endpoint was platelet reactivity. The main safety endpoint was excessive CABG-surgery related bleeding. In October 2010, The Medicines Company initiated a Phase 3 clinical trial called PHOENIX to evaluate cangrelor in patients undergoing percutaneous coronary intervention (PCI).

The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.



Contact:
Michael Mitchell
The Medicines Company
+973-290-6000

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 17.01.2012 - 21:34 Uhr
Sprache: Deutsch
News-ID 105095
Anzahl Zeichen: 0

contact information:
Town:

PARSIPPANY, NJ

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 291 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"The Medicines Company's Cangrelor Bridge Trial Published in the Journal of the American Medical Association"
steht unter der journalistisch-redaktionellen Verantwortung von

The Medicines Company (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

The Medicines Company to Participate in Upcoming Investor Conference Webcasts ...

PARSIPPANY, NJ -- (Marketwired) -- 11/27/13 -- The Medicines Company (NASDAQ: MDCO) is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference on December 4th at 12:30 PM Eastern Time. MDCO is also scheduled to present at the Opp ...

European Medicines Agency Accepts Marketing Authorization Application for The Me ...

PARSIPPANY, NJ -- (Marketwired) -- 11/21/13 -- The Medicines Company (NASDAQ: MDCO) today announced that the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for the investigational hemostatic agent ...

FDA Grants QIDP Designation to The Medicines Company's Investigational Anti ...

PARSIPPANY, NJ -- (Marketwired) -- 11/12/13 -- The Medicines Company (NASDAQ: MDCO) today announced that the U.S. Food and Drug Administration (FDA) has designated oritavancin as a Qualified Infectious Disease Product (QIDP). The QIDP designation pr ...

Alle Meldungen von The Medicines Company